Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

“Late for testing, early for antiretroviral therapy, less likely to die”: results from a large HIV cohort study in China, 2006–2014

  • 1,
  • 1Email author,
  • 2, 3,
  • 1,
  • 1 and
  • 1
BMC Infectious Diseases201818:272

https://doi.org/10.1186/s12879-018-3158-x

Received: 31 October 2017

Accepted: 22 May 2018

Published: 13 June 2018

Abstract

Background

Timely HIV testing and initiation of antiretroviral therapy are two major determinants of survival for HIV-infected individuals. Our study aimed to explore the trend of late HIV/AIDS diagnoses and to assess the factors associated with these late diagnoses in China between 2006 and 2014.

Methods

We used data from the Chinese Comprehensive Response Information Management System of HIV/AIDS (CRIMS). All individuals who tested positive for HIV between 2006 and 2014 in China and were at least 15 years of age were included. A late diagnosis was defined as an instance in which an individual was diagnosed as having AIDS or WHO stage 3 or 4 HIV/AIDS, or had a CD4 cell count less than 200 cells/mm3 at the time of diagnosis.

Results

Among the 528,234 individuals (≥15 years old) newly diagnosed with HIV between 2006 and 2014, 179,700 (34.0%) people were considered to have received late diagnoses. The late diagnosis rate decreased from 33.9% in 2006 to 29.7% in 2014 (P < 0.01). Late diagnoses were more likely to be found among those who were 45–54 years old (adjusted odds ratio [aOR]: 3.25, 95% confidence interval [CI]: 3.17–3.34) or 55+ years old (OR: 2.94, 95% CI: 2.86–3.02), male (aOR: 1.15, 95% CI: 1.13,1.17), employed as a farmer or rural laborer (aOR: 1.13, 95% CI: 1.11–1.14), infected through blood or plasma transfusion (aOR: 4.18, 95% CI: 4.02, 4.35), diagnosed at hospitals (OR: 1.17, 95% CI: 1.15, 1.19), of Han ethnicity (aOR: 1.30, 95% CI: 1.28, 1.32), and married (OR: 1.12, 95% CI: 1.11,1.13). Of those people living with HIV (PLHIV) who received late diagnoses, 7.4%(8637) and 46.1%(28,462) ultimately died with or without receiving antiretroviral therapy within a year of diagnosis, respectively.

Conclusion

A large proportion of individuals with HIV/AIDS receive late diagnoses, and this proportion has witnessed a slight decline in recent years. Expanded testing is needed to increase early HIV diagnosis and antiretroviral therapy should be recommended to all diagnosed individuals as early as possible to reduce AIDS-related death.

Keywords

  • Late diagnosis
  • Early mortality
  • ART
  • China

Background

The introduction and expansion of highly active antiretroviral therapy (HAART) has proven to be one of the most remarkable public health measures in reducing the morbidity and mortality caused by the Human Immunodeficiency Virus (HIV) [14]. UNAIDS sets an ambitious treatment target to help end the AIDS epidemic: By 2020, 90% of all people living with HIV know their HIV status, 90% of people with diagnosed HIV receive antiretroviral therapy (ART) and 90% of all people on HIV treatment achieve viral suppression [5]. However, delayed testing as well as stigma and discrimination against infected individuals places them at risk of receiving delayed antiretroviral therapy [6].

Early detection of HIV infection is a critical factor in controlling the spread of HIV [7]. Timely ART is associated with a better prognosis among HIV-infected individuals and lower rates of disease progression [8]. Prompt linkages with health care systems at the start of ART yields the maximum benefits of HIV medical treatment for people living with HIV (PLHIV) [9] while decreasing the sexual transmission rate of HIV [1013]. A late diagnosis is detrimental to both the individual infected with HIV and the community for two reasons. First, in the absence of timely initiation of ART, the majority of patients will suffer the deleterious effects of HIV infection due to the gradual failure of the immune system, ranging from infection by opportunistic diseases to even death. Second, the propensity for HIV transmission by untested and hence unaware PLHIV is greater [14, 15] than for those made aware of their HIV status.

Developed countries such as the USA, Canada, and the European Union have been successful in addressing some of the key operational factors hindering the effective management of diseases affecting PLHIV [1621]. However, it is estimated that 30% of PLHIV in the European Union [9] remain undiagnosed, while evidence from the United States suggests that 25% of the undiagnosed population is responsible for the transmission of new HIV infections in 54% of cases [7, 22].

The proportion of those who received late diagnoses in industrialized countries is most often reported at between 25 and 45% of all newly HIV-diagnosed cases [23]. Though the largest proportion of undiagnosed PLHIV resides in developing countries, little research describing their characteristics has been conducted in these settings. In China, HIV voluntary counseling and testing (VCT) is free and can be widely accessed in urban areas. However, this free testing strategy has not been able to prevent a large proportion of cases of late HIV diagnosis for several reasons [24]. Incomplete HIV screening among STD patients in China has been cited as one important cause of missed opportunities for HIV testing [25].

Our study aimed to identify characteristics and trends of cases of late HIV/AIDS diagnosis, and to assess the factors associated with late diagnosis, early mortality, and ART initiation in China between 2006 and 2014.

Methods

Data sources and definitions

In China, all newly diagnosed HIV/AIDS cases and all recipients of free ART are registered into the Chinese Comprehensive Response Information Management System of HIV/AIDS (CRIMS). CRIMS is managed by the National Centre for AIDS/STD Control and Prevention (NCAIDS) of the Chinese Centre for Disease Control and Prevention (China CDC) and includes the National Case Reporting Database (NCRD) and the National Free Antiretroviral Therapy Database (NFATD). The NCRD collects data on newly diagnosed HIV/AIDS cases, including demographic characteristics, route of infection, site of HIV diagnosis or blood sample source, date of diagnosis, laboratory test results with corresponding test date, and date of death. These cases are followed up every 6 months. During each follow-up, CD4 cell count, counseling and behavior intervention, and other referral services are performed. The NCRD also collects additional data during each follow-up visit, including changes in demographic information, disease stage, CD4 cell count, information on behavioral determinants, and details of ART. The NFATD includes all cases that meet the national treatment criteria and have received free treatment. In China, the national criteria for treatment is a CD4 cell count of less than 350 cells/mm3 (as of 2009) and later, of less than 500 cells/mm3 (as of 2014), or being reported as having AIDS, or having WHO stage 3 or 4 HIV/AIDS and having been referred for ART [2629]. Information on the individual’s drug regiment during each follow-up visit is recorded and then uploaded to the CRIMS.

A detailed description of the NCRD and NFATD has been published elsewhere [26], including a discussion of quality control of lab work [28]. There have been several important ART studies based on the data from these two systems in recent years [2729]. In this study, we updated the results in continuation with earlier findings from the cohort study [27]. We included all newly diagnosed HIV/AIDS cases between 1 January 2006 and 31 December 2014 in mainland China involving individuals aged 15 years and over and excluded individuals who could not be located by local CDCs during follow-up visits.

There were several explanations for the term “late diagnosis” [3032]. In this study, we classified a case as a “late diagnosis” if an individual was reported as 1) having been diagnosed with AIDS or 2) having been diagnosed with WHO stage 3 or 4 HIV/AIDS, or 3) having an initial CD4 cell count of less than 200/mm3 within one year after the date of HIV diagnosis. Early mortality was defined as death from AIDS-related causes within one year of an HIV/AIDS diagnosis. Cases without a death certificate or without being lost to follow-up as of 31 December 2014, were assumed to be alive. Cases who died of overdose drug use or suicide were excluded.

We defined preventable early mortality as the estimated number of AIDS-related deaths within one year of diagnosis attributed to late diagnosis. The number of preventable early mortality equals to the number of observed AIDS-related deaths within one year of diagnosis minus the estimated number of AIDS-related deaths within one year of diagnosis according to the early mortality rate of those who received timely HIV diagnoses.

Statistical analysis

We used SAS software (version 9.4; SAS Institute; Cary, NC) for data analysis and MapInfo Professional software (version 15.0; Pitney Bowes; USA) for maps creation. Descriptive analysis was done for late diagnoses across all cases, including gender, age at HIV diagnosis, marital status, education level, route of transmission, ethnic group, and screening sites. Screening sites were categorized into three groups: VCT sites, hospitals, and detention centers. Transmission routes were classified into five groups: heterosexual, homosexual, injection drug use, sexual contact and injection drug use, and former paid blood/plasma donation. Odds ratio (OR) was used to assess the factors associated with late diagnosis by means of univariate and multivariate logistic regression models. Variables for which P values were less than 0.05 were considered to be statistically significant.

Results

A total of 563,961 individuals were newly diagnosed with HIV infection in mainland China during the period between 1 January 2006 and 31 December 2014. A total of 35,727 subjects were excluded from this analysis, as 28,544 cases could not be traced after the initial positive tests and 7183 cases concerned individuals were under 15 years of age (Fig. 1). Among the remaining 528,234 individuals, the majority were male (72.7%), married (50.2%), had attained a middle school level education or higher (60.8%), heterosexual (63.2%), and belonged to the Han ethnic group (74.6%). Most were diagnosed a t hospitals (44.7%) and VCT sites (28.4%) (Table 1).
Figure 1
Fig. 1

Study profile

Table 1

Demographic Characteristics and factors associated with late diagnosis in China between 2006 and 2014 (N = 528,234)

Categories

Newly diagnosed (age > 14 years old)

n (%) of Late diagnosis

Unadjusted OR (95%CI)

Adjusted OR (95%CI)

Total

528,234

179,700(34.0)

_

_

Year of HIV diagnosis

 2006

26,027

8823(33.9)

Ref.

Ref.

 2007

32,538

11,427(35.1)

1.06(1.02–1.09)

1.04(1.00–1.08)

 2008

40,690

13,734(33.8)

0.99(0.96–1.03)

0.93(0.89–0.96)

 2009

48,163

17,073(35.4)

1.07(1.04–1.11)

0.99(0.95–1.02)

 2010

53,375

19,700(36.9)

1.14(1.11–1.18)

0.99(0.96–1.03)

 2011

67,256

23,944(35.6)

1.08(1.05–1.11)

0.89(0.86–0.92)

 2012

76,716

26,598(34.7)

1.04(1.01–1.07)

0.84(0.81–0.87)

 2013

85,518

29,291(34.3)

1.02(0.99–1.05)

0.82(0.79–0.85)

 2014

97,951

29,110(29.7)

0.83(0.80–0.85)

0.65(0.63–0.68)

Sex

 Female

144,013

49,803(34.6)

Ref.

Ref.

 Male

384,221

129,897(33.8)

0.97(0.95–0.98)

1.15(1.13–1.17)

Age groups(years)

 15–24

74,796

12,174(16.3)

Ref.

Ref.

 25–34

163,089

44,161(27.1)

1.91(1.87–1.95)

187(1.82–1.91)

 35–44

132,507

51,750(39.1)

3.30(3.22–3.37)

2.78(2.72–2.85)

 45–54

70,158

32,262(46.0)

4.38(4.27–4.49)

3.25(3.17–3.34)

 55+

87,684

39,353(44.9)

4.19(4.09–4.29)

2.94(2.86–3.02)

Marital status

 Single, divorced, or widowed

256,895

74,319(28.9)

Ref.

Ref.

 Married or lives with partner

264,977

104,087(39.3)

1.59(1.57–1.61)

1.12(1.11–1.13)

Education

 Middle school or more

331,210

111,091(33.5)

Ref.

Ref.

 Primary school or less

191,811

67,212(35.0)

1.07(1.06–1.08)

0.87(0.86–0.89)

Occupation

 Other

278,138

84,141(30.3)

Ref.

Ref.

 Farmer or rural laborer

250,096

95,559(38.2)

1.43(1.41–1.44)

1.13(1.11–1.14)

Ethnic group

 Other

134,406

35,356(26.3)

Ref.

Ref.

 Han

393,828

144,344(36.7)

1.62(1.60–1.64)

1.30(1.28–1.32)

Route of HIV infection

 Heterosexual

333,753

126,658(37.9)

Ref.

Ref.

 Homosexual

85,252

20,891(24.5)

0.53(0.52–0.54)

0.71(0.70–0.73)

 Injection drug use

73,834

14,111(19.1)

0.39(0.38–0.39)

0.63(0.61–0.64)

 Sexual contact and injection drug use

5257

1147(21.8)

0.46(0.43–0.49)

0.71(0.66–0.76)

 Blood or plasma transfusion

16,767

12,910(77.0)

5.47(5.28–5.68)

4.18(4.02–4.35)

Sites of diagnosis

 VCT centers

150,157

54,260(36.1)

Ref.

Ref.

 Hospitals

236,047

97,220(41.2)

1.24(1.22–1.25)

1.17(1.15–1.19)

 Detention centers

43,231

5087(11.8)

0.24(0.23–0.24)

0.35(0.34–0.37)

others

98,799

23,133(23.4)

0.54(0.53–0.55)

0.59(0.58–0.61)

Migrant populationa

 No

402,155

143,160(35.6)

Ref.

Ref.

 Yes

126,079

36,540(29.0)

0.74(0.73–0.75)

0.94(0.93–0.96)

aMigrant population: people migrated from one county to another county and stay there for at least six months

In this cohort, 179,700 (34.0%) individuals newly diagnosed with HIV infection were classified as “late diagnosis” cases in accordance with the definition. The late diagnosis rate decreased from 33.9% in 2006 to 29.7% in 2014 (P < 0.01) (Fig. 2). The proportion of cases of late diagnosis were more than 55 % among four provinces in 2006, three provinces in 2010 and none in 2014 (Fig. 3).
Figure 2
Fig. 2

Proportions of individuals diagnosed late in different calendar years of diagnosis (X axis: calendar year of diagnosis; Y axis: proportion of late diagnosis)

Figure 3
Fig. 3

Proportions of individuals diagnosed late in different calendar years of diagnosis among 31 provinces in China (a: year of 2006, b: year of 2010, c: year of 2014)

The proportion of cases of late diagnosis was greater among those who were over 45 years old, married, farmers or rural laborers, and of Han ethnicity, infected through heterosexual transmission or former blood/plasma transfusion, diagnosed at hospitals, (Table 1). In addition, our results indicated that cases of late diagnosis increased with an increase in age in all calendar years during the study period.

As per our results, factors independently associated with an increased likelihood of late diagnosis were being male (aOR: 1.15, 95% CI: 1.13–1.17), being in an older age group (aOR: 3.25, 95% CI: 3.17–3.34 for 45–54 years old; aOR: 2.94, 95% CI: 2.86–3.02 for 55+ years old), having acquired HIV infection through former blood or plasma transfusion (aOR: 4.18, 95% CI: 4.02–4.35), being of Han ethnicity (aOR: 1.30, 95% CI: 1.28–1.32), being married or living with a partner (aOR: 1.15, 95% CI: 1.13–1.17), being farmers (aOR: 1.13, 95% CI: 1.11–1.14), and being tested at hospitals (aOR: 1.17, 95% CI: 1.15–1.19).

Around 52.0% of newly diagnosed cases (274,552) had their CD4 cell count results available within one month of HIV diagnosis (Table 2). This proportion increased from 19.0% in 2006 to 65.8% in 2014. Furthermore, this proportion was the lowest (29.7%) among those who were infected through injection drug use. Those who were diagnosed at VCT clinics received a timely (within one month) CD4 cell count testing of 60.9%.
Table 2

Initial CD4 cell counts after diagnosed of HIV newly diagnosed individuals in China between 2006 and 2014 (N = 528,234)

Characteristic

Newly diagnosed (age > 14 years old)

Initial CD4 cell count within one month

Initial CD4 cell count within one year

Initial CD4 cell counts < 200 cell/ul within one year

n

%

n

%

n

%

Year of HIV diagnosis

 2006

26,027

4950

19.0

9129

35.1

3901

42.7

 2007

32,538

8856

27.2

15,621

48.0

6282

40.2

 2008

40,690

14,475

35.6

23,979

58.9

8491

35.4

 2009

48,163

20,327

42.2

32,083

66.6

11,321

35.3

 2010

53,375

25,110

47.0

40,073

75.1

13,511

33.7

 2011

67,256

35,950

53.5

54,378

80.9

18,002

33.1

 2012

76,716

45,550

59.4

66,064

86.1

20,444

30.9

 2013

85,518

54,931

64.2

76,191

89.1

23,474

30.8

 2014

97,951

64,403

65.8

86,482

88.3

25,669

29.7

Route of HIV infection

 Heterosexual

333,753

183,602

55.0

264,332

79.2

96,527

36.5

 Homosexual

85,252

57,299

67.2

78,895

92.5

15,515

19.7

 Injection drug use

73,834

21,958

29.7

40,713

55.1

9168

22.5

 Sexual contact and injection drug use

5257

1760

33.5

3257

62.0

777

23.9

 Blood or plasma transfusion

16,767

7006

41.8

11,833

70.6

7142

60.4

Sites of diagnosis

 VCT centers

150,157

91,425

60.9

124,603

83.0

39,141

31.4

 Hospitals

236,047

118,702

50.3

176,834

74.9

73,114

41.3

 Detention centers

43,231

12,397

28.7

23,395

54.1

3196

13.7

 others

98,799

52,028

52.7

79,168

80.1

15,644

19.8

 Total

528,234

274,552

52.0

404,000

76.5

131,095

32.4

Our results indicate that 76.5% (404,000) of newly HIV diagnosed individuals received testing for CD4 cell count within one year of HIV diagnosis (Table 2). Of these individuals, 32.4% (131,095) had a CD4 cell count less than 200 cells/mm3. The proportion with a CD4 cell count test administered within one year increased during the study period from 35.1% in 2006 to 88.3% in 2014, and the proportion of CD4 cell count less than 200 cells/mm3 decreased from 42.7% in 2006 to 29.7% in 2014. Those infected through former blood or plasma transfusion witnessed a high proportion of CD4 cell count less than 200 cells/mm3. The proportion of CD4 cell count less than 200 cells/mm3 increased with age, from 13.3% in 15–24 age group to 44.8% in 55+ age group.

Early mortality and access to ART

Of the 179,700 individuals who received late diagnoses, excluding 1404 individuals who died of overdose drug use or suicide, the proportions receiving ART within one month of diagnosis and within one year of diagnosis were 30.1 and 65.4%, respectively. The percentage of the individuals who received late diagnoses, received ART, and died within one month of diagnosis was 0.51%. The percentage of the individuals who received late diagnoses, received ART, and died within one year of diagnosis was 7.4% (Table 3). 17.4% of individuals who received late diagnoses but did not receive ART died within one month of diagnosis, and 46.1% of those who received late diagnoses without ART died within one year of diagnosis. Upon further analysis, the early mortality was 20.8% (37,099/178,296) among those who received late diagnoses and 9.6% (32,626/341,072) among those with timely diagnoses (P < 0.01).
Table 3

Early mortality among late diagnosed individuals with or without ART, by month (N = 178,296)

Duration of time from diagnosis

Initial CD4 counts

ON ART

NO ART

N

No. of deatha

% of death

Na

No. of deatha

% of death

One month

0–49

33,897

325

0.96

15,344

2449

15.96

50–99

19,220

63

0.33

7153

516

7.21

100–199

37,747

44

0.12

13,934

330

2.37

200–349

17,685

14

0.08

6718

81

1.21

350–499

5135

3

0.06

3301

32

0.97

500-

2041

0

0.00

1977

10

0.51

No CD4 test

848

142

16.75

13,296

7316

55.02

subtotal

116,573

591

0.51

61,723

10,734

17.39

Three months

0–49

33,897

1551

4.58

15,344

5705

37.18

50–99

19,220

390

2.03

7153

1399

19.56

100–199

37,747

283

0.75

13,934

1000

7.18

200–349

17,685

61

0.34

6718

201

2.99

350–499

5135

15

0.29

3301

77

2.33

500-

2041

3

0.15

1977

34

1.72

No CD4 test

848

398

46.93

13,296

9674

72.76

subtotal

116,573

2701

2.32

61,723

18,090

29.31

Six months

0–49

33,897

2950

8.70

15,344

7963

51.90

50–99

19,220

880

4.58

7153

2253

31.50

100–199

37,747

678

1.80

13,934

1684

12.09

200–349

17,685

147

0.83

6718

359

5.34

350–499

5135

39

0.76

3301

157

4.76

500-

2041

14

0.69

1977

70

3.54

No CD4 test

848

560

66.04

13,296

10,838

81.51

subtotal

116,573

5268

4.52

61,723

23,324

37.79

Twelve months

0–49

33,897

4521

13.34

15,344

9796

63.84

50–99

19,220

1520

7.91

7153

3100

43.34

100–199

37,747

1385

3.67

13,934

2654

19.05

200–349

17,685

361

2.04

6718

628

9.35

350–499

5135

107

2.08

3301

307

9.30

500-

2041

53

2.60

1977

141

7.13

No CD4 test

848

690

81.37

13,296

11,836

89.02

subtotal

116,573

8637

7.41

61,723

28,462

46.11

aThose who died of overdose drug use or suicide were excluded

Among PLHIV who received late diagnoses, the proportion experiencing early mortality declined annually from 2006 to 2014 with an increase in the proportion receiving ART (Table 4). The early mortality rates for individuals who received late diagnoses were 29.5% in 2006 and 14.5% in 2014. At the same time, the treatment coverage rates for these individuals within one year of diagnosis were 39.5% in 2006 and 73.9% in 2014. The treatment coverage rate for those who reported having had sex with men was highest (82.8%) (p < 0.01), therefore, this group also experienced the lowest rate of early mortality (8.0%) (Table 4).
Table 4

Access to ART and early mortality among late diagnosis individuals within one year of diagnosis between 2006 and 2014 (N=178,296)

Characteristics

Late diagnosis (age>14 years old)*

N (% of access to ART within one month)

N (% of access to ART within one year)

N (% of died after receiving ART)

χ2

P-value b

Year of HIV diagnosis

    

141.52

<0.01

 2006

8675

1436(16.6)

3429(39.5)

267(7.8)

  

 2007

11252

2105(18.7)

5126(45.6)

341(6.7)

  

 2008

13535

3051(22.5)

7387(54.6)

568(7.7)

  

 2009

16874

3906(23.1)

9527(56.5)

621(6.5)

  

 2010

19532

4498(23.0)

12021(61.5)

679(5.6)

  

 2011

23741

6383(26.9)

16355(68.9)

1076(6.6)

  

 2012

26445

8524(32.2)

19038(72.0)

1495(7.9)

  

 2013

29192

11068(37.9)

22212(76.1)

1897(8.5)

  

 2014

29050

12668(43.6)

21478(73.9)

1693(7.9)

  

Sex

    

137.54

<0.01

 Female

49561

15132(30.5)

32806(66.2)

1959(6.0)

  

 Male

128735

38507(29.9)

83767(65.1)

6678(8.0)

  

Age group (years)

    

871.48

<0.01

 15-24

12082

3107(25.7)

8305(68.7)

317(3.8)

  

 25-34

43688

12146(27.8)

28734(65.8)

1436(5.0)

  

 35-44

51244

15499(30.2)

33684(65.7)

2430(7.2)

  

 45-54

32084

10846(33.8)

21947(68.4)

1832(8.3)

  

 55+

39198

12041(30.7)

23903(61.0)

2622(11.0)

  

Marital status

    

11.08

<0.01

 Single, divorced, or widowed

73626

20957(28.5)

48061(65.3)

3411(7.1)

  

 Married or lives with partner

103411

32483(31.4)

67970(65.7)

5177(7.6)

  

Education

    

488.54

<0.01

 Middle school or more

110338

34898(31.6)

77177(69.9)

4792(6.2)

  

 Primary school or less

66599

18585(27.9)

39012(58.6)

3826(9.8)

  

Occupation

    

663.26

<0.01

 Other

83510

25305(30.3)

57787(69.2)

3130(5.4)

  

 Farmer or rural laborer

94786

28334(29.9)

58786(62.0)

5507(9.4)

  

Ethnic group

    

16.57

<0.01

 Others

34969

9013(25.8)

19866(56.8)

1335(6.7)

  

 Han

143327

44626(31.1)

96707(67.5)

7302(7.6)

  

Route of HIV infection

    

622.49

<0.01

 Heterosexual

126054

40124(31.8)

83978(66.6)

6547(7.8)

  

 Homosexual

20832

6951(33.4)

17167(82.4)

646(3.8)

  

 Injection drug use

13531

1955(14.4)

5809(42.9)

372(6.4)

  

 Sexual contact and IDU

1102

245(22.2)

560(50.8)

31(5.5)

  

 Blood or plasma transfusion

12841

3722(29.0)

7457(58.1)

917(12.3)

  

Sites of diagnosis

    

681.88

<0.01

 VCT centers

53825

17809(33.1)

36452(67.7)

2346(6.4)

  

 Hospitals

96608

29659(30.7)

62791(65.0)

5683(9.1)

  

 Detention centers

4859

197(4.1)

1563(32.2)

62(4.0)

  

 others

23004

5974(26.0)

15767(68.5)

546(3.5)

  

Migrant population a

    

10.03

<0.01

 No

142108

43658(30.7)

93717(65.9)

7056(7.5)

  

 Yes

36188

9981(27.6)

22856(63.2)

1581(6.9)

  

Initial CD4+ cell count

    

10298.66

<0.01

 0-49

49241

18191(36.9)

33897(68.8)

4521(13.3)

  

 50-99

26373

9778(37.1)

19220(72.9)

1520(7.9)

  

 100-199

51681

17268(33.4)

37747(73.0)

1385(3.7)

  

 200-349

24403

6167(25.3)

17685(72.5)

361(2.0)

  

 350-499

8436

1177(14.0)

5135(60.9)

107(2.1)

  

 500-

4018

476(11.8)

2041(50.8)

53(2.6)

  

 No CD4 records

14144

582(4.1)

848(6.0)

690(81.4)

  

Total

178296

53639(30.1))

116573(65.4)

8637(7.4)

  

aThose who died of overdose drug use or suicide were excluded

bThe proportion of those who died after ART within one year is compared by different characteristics

Estimation of preventable early mortality

Early mortality among those who received timely HIV diagnoses was 9.6%. Basing our assumptions of previous research [3032], we presumed in our study that 1) early mortality would be reduced to 9.6% if there were no late diagnoses; 2) there would be no effect on deaths occurring more than a year after diagnosis; and 3) there would no other competing risks. Based on these conjectures, only 17,116 deaths would have been expected from 2006 to 2014 within a year of diagnosis if the diagnosis was timely. That is, 19,983 deaths would have been avoided during this period, compared to the 37,099 deaths actually observed among the group with late HIV diagnoses. Therefore, the current burden of early mortality would be reduced by about 53.9%.

Discussion

It has been thirty years since HIV testing first became available [33]. Despite the decades of availability of testing, it was estimated that at least one-fourth of PLHIV worldwide were unaware of their infection [24, 3439], and that this ratio could be even higher in China [24].Our results indicate that promoting timely diagnosis and treatment provided a survival advantage to PLHIV, and that almost 54% of deaths that occurred within one year of HIV diagnosis could thus be prevented. Our study expanded upon the existing literature [16, 32, 37, 40, 41] by evaluating late diagnoses among all HIV cases identified between 2006 and 2014 in China, by assessing and mapping the trend of late diagnosis over time and by evaluating factors associated with late diagnosis among HIV cases in China.

In our study, 34.0% of HIV cases were considered to have received late diagnoses between 2006 and 2014. The late diagnosis rate fluctuated from 2006 to 2014, but slightly decreased from 36.9% in 2010 to 29.7% in 2014 (P < 0.01). This declining could be due to the implementation of the provider-initiated HIV testing and counseling (PITC) strategy since 2009. After the initiating of PITC, the HIV testing was significantly scaled up in most of provinces in China [37, 38, 42]. The scaling up of HIV self-testing in China could be another reason for this phenomenon. For example, around 30% of MSM in China self-reported that they ever self-tested in 2016 [36].

The propensity to receive late HIV testing was greater for older people, those who had acquired HIV infection through former blood or plasma transfusion or heterosexual behaviors, individuals of Han ethnicity, married individuals, and farmers. These results are consistent with the findings of previous studies [31, 43], with the exception of some studies in the U.S. indicated that younger people was more likely to receive late testing [44, 45]. In recent years, spouses’ and regular partners’ testing was scaled up in China, because of a series of national and provincial laws, regulations, and policy initiatives.

The majority of late diagnoses occurred among those who were infected with HIV through heterosexual behaviors. It indicated that there might have been a prolonged period of transmission risk to their sexual partners. Strategies, promoting rapid HIV testing at primary level of health institutions, promoting HIV self-testing, and increasing collaboration with community based organizations (CBOs), should be further implemented. Also, the risk of late diagnosis was significantly higher for those who were infected through former blood or plasma transfusion. Illegal paid plasma donation was prominent in central China in the 1990s and resulted in the infection of the majority of donors with the HIV virus [26, 46, 47]. Most of these PLHIV did not seek testing due to societal discrimination and stigma against HIV. As a result, they were diagnosed with HIV only after they experienced symptoms. Most of these people are located in four provinces in central China, as shown in Fig. 3.

However, the proportion of late testing has decreased among men who have sex with men (MSM) and injection drug users in recent years. This finding may have been due to ongoing intervention programs that promoted testing in these high risk groups [48, 49], such as methadone maintenance treatment (MMT) for injection drug users and free HIV testing for MSM provided by CBOs and VCT clinics. Similar results have been found in other studies [45].

Individuals who present at an advanced stage of immunosuppression are at high risk of clinical events and death and are more likely to have a poor response when they start ART [50, 51]. The proportion of people receiving late diagnoses among newly diagnosed individuals remained at more than 30% between 2006 and 2013. However, this proportion has been in decline since 2010. In an era where effective and free testing and free treatment options are available in China, it is alarming that there is a substantial proportion of people were late diagnosed, and they are at higher risk of early death. A records-based retrospective cohort study in China found that the highest mortality rates for AIDS-related death and all-cause death were found in the first year of follow up after HIV diagnosis [52]. This phenomenon could be explained by the fact that about half of the participating cases had already progressed to AIDS before being identified, progression to AIDS was one of the strongest risk factors for AIDS-related death, with an aHR of 7.42 [52].

Individuals who present at an advanced stage of immunosuppression are at high risk of AIDS related diseases and death as well as more likely to have a poorer response to ART [36, 53]. Both HIV testing and ART have been free for PLHIV in China since 2003 [54]. In spite of this policy, our results indicate that as many as 30% of all newly diagnosed individuals received late diagnoses. Shortening the time from infection to measurement of CD4 cell counts could be an important window for early treatment. We infer that the time from infection to CD4 measurement is a useful indicator for monitoring delays in access to HIV medical care among newly diagnosed PLHIV [55]. In our analysis, 52.0% of newly diagnosed individuals had their CD4 cell counts available within one month of HIV diagnosis. This proportion increased from 19.0% in 2006 to 65.8% in 2014. It is very important for late diagnosed individuals to receive CD4 cell count testing immediately, so that they can receive referrals for timely ART and thus reduce their risk of death. In our study, this proportion of cases received ART within one month after the diagnoses increased from 16.6% in 2006 to 43.6% in 2014. The average proportion of having CD4 counts within one year was 76% from 2006 to 2014. The causes of not having CD4 counts testing within one year included death before having CD4 counts, lost to follow up, and inconvenience to access to CD4 count test. To shorten the time to CD4 cell count testing and to improve access to regular testing and treatment, efforts were taken in the past few years to dramatically improve referrals and integration of patient tracking between the health facilities responsible for patients follow up, CD4 cell count testing, and ART delivery [56].

Our analysis suggests that groups at high risk of late diagnosis should be targeted for appropriate public health intervention and encouraged to seek earlier treatment. Scaling up HIV testing is one of the important strategies in implementing this goal. This strategy may bring out a greater proportion of hidden individuals infected with HIV [57]. Another strategy would be to consider population-wide screening for HIV, such as for patients in hospitals. In the U.S., the CDC recommends routine HIV counseling and testing in healthcare settings for patients aged 13–64 years, unless the local HIV prevalence is known to be less than 0.1% [1].

There are some limitations to consider while interpreting our findings. Firstly, 2.3% (12,352/528234) individuals were lost to follow-up after HIV diagnoses, and then CD4 cell counts data or having WHO stage 3 or 4 of them were not available at diagnosis. Thus, it is possible that some individuals with AIDS may have been misclassified as having HIV. However, the resulting misclassification will be non-differential and might bias the estimates towards the null, because the proportion of individuals misclassified does not depend on the individual with respect to other variables on the analysis [58]. Secondly, our results couldn’t assess differences in mortality in late diagnosed individuals who access to ART based on ART regimen. It needs further research.

Conclusion

Even with these limitations, our results still indicate that it is important to increase the accessibility of HIV testing services. Routine testing for most individuals has been recommended as a cost-effective strategy and efforts to promote such testing should be developed [40, 53].

Abbreviations

ART: 

Antiretroviral Therapy

CBOs: 

Community Based Organizations

CDC: 

Centre for Disease Control and Prevention

CRIMS: 

Chinese Comprehensive Response Information Management System of HIV/AIDS

HAART: 

Highly active antiretroviral therapy

HIV: 

Human Immunodeficiency Virus

MMT: 

Methadone Maintenance Treatment

MSM: 

Men Who Have Sex with Men

NCAIDS: 

National Centre for AIDS/STD Control and Prevention

NCRD: 

National Case Reporting Database

NFATD: 

National Free Antiretroviral Therapy Database

OR: 

Odds Ratio

PITC: 

Provider-Initiated HIV Testing and Counseling

PLHIV: 

People Living with HIV

VCT: 

Voluntary Counseling and Testing

Declarations

Acknowledgements

The authors thank all of the health care and laboratory staff at all levels who participated in HIV/AIDS diagnoses, follow-up and data collection for this study.

Funding

This study was funded from the National Health and Family Planning Commission of the People’s Republic of China (grant#131–11–0001-0501). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

HT, YM, WT, JH, JX, and JL contributed to the study design and authored the study. HT and YM, conceived and designed the study. HT analyzed the data. HT, YM, and WT wrote the initial draft of this manuscript. HT and YM had full access to all of the data in the study and YM had responsibility for the decision to submit the final manuscript for publication. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This study was a secondary data analysis using existing Chinese government HIV/AIDS CRIMS data. Therefore, no additional study specific informed consent was necessary for this current study. Patient records and information were de-identified prior to analysis. This study protocol was reviewed and approved by the Institutional Review Board of the National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention (approval #X160310409).

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
(2)
University of North Carolina at Chapel Hill Project-China, Guangzhou, China
(3)
School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, USA

References

  1. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1–17.PubMedGoogle Scholar
  2. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the international AIDS society--USA panel. Top HIV Med. 2006;3:827–43.Google Scholar
  3. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;(13):853–60.Google Scholar
  4. Detels R, Muñoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Stud Invest JAMA. 1998;17:1497–503.Google Scholar
  5. Sidibé M, Loures L, Samb B. The UNAIDS 90-90-90 target: a clear choice for ending AIDS and for sustainable health and development. J Int AIDS Soc. 2016;(1):211–33.Google Scholar
  6. Centers for Disease Control and Prevention. (CDC). Missed opportunities for earlier diagnosis of HIV infection--South Carolina, 1997-2005. MMWR Morb Mortal Wkly Rep. 2006;47:1269–72.Google Scholar
  7. Centers for Disease Control and Prevention (CDC). Adoption of protective behaviors among persons with recent HIV infection and diagnosis-Alabama, New Jersey, and Tennessee, 1997-1998. MMWR Morb Mortal Wkly Rep. 2000;23:512–5.Google Scholar
  8. Centers for Disease Control and Prevention. (CDC). Late versus early testing of HIV--16 sites, United States, 2000-2003. MMWR Morb Mortal Wkly Rep. 2003;25:581–6.Google Scholar
  9. García F, de Lazzari E, Plana M, et al. Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. J Acquir Immune Defic Syndr. 2004;(2):702–13.Google Scholar
  10. McClelland RS, Baeten JM. Reducing HIV-1 transmission through prevention strategies targeting HIV-1-seropositive individuals. J Antimicrob Chemother. 2006;57(2):163–6.View ArticlePubMedGoogle Scholar
  11. Chamot E, Coughlin SS, Farley TA, et al. Gonorrhea incidence and HIV testing and counseling among adolescents and young adults seen at a clinic for sexually transmitted diseases. AIDS. 1999;(8):971–9.Google Scholar
  12. George N, Green J, Murphy S. Sexually transmitted disease rates before and after HIV testing. Int J STD AIDS. 1998;(5):291–3.Google Scholar
  13. Otten MW Jr, Zaidi AA, Wroten JE, et al. Changes in sexually transmitted disease rates after HIV testing and posttest counseling, Miami, 1988 to 1989. Am J Public Health. 1993;(4):529–33.Google Scholar
  14. Delpierre C, Cuzin L, Lert F. Routine testing to reduce late HIV diagnosis in France. BMJ. 2007;(7608):1354–6.Google Scholar
  15. Marks G, Crepaz N, Senterfitt JW, et al. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. JAIDS. 2005;(4):446–53.Google Scholar
  16. Mukolo A, Villegas R, Aliyu M, et al. Predictors of late presentation for HIV diagnosis: a literature review and suggested way forward. AIDS Behav. 2013;(1):5–30.Google Scholar
  17. Yang B, Chan SK, Mohammad N, et al. Late HIV diagnosis in Houston/Harris County, Texas, 2000-2007. AIDS Care. 2010;6:766–74.View ArticleGoogle Scholar
  18. Brinkhof MW, Dabis F, Myer L, et al. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ. 2008;7:559–67.Google Scholar
  19. Wolbers M, Bucher HC, Furrer H, et al. Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV cohort study. HIV Med. 2008;(6):397–405.Google Scholar
  20. Krawczyk CS, Funkhouser E, Kilby JM, et al. Factors associated with delayed initiation of HIV medical care among infected persons attending a southern HIV/AIDS clinic. South Med J. 2006;(5):472–81.Google Scholar
  21. Bamford LP, Ehrenkranz PD, Eberhart MG, et al. Factors associated with delayed entry into primary HIV medical care after HIV diagnosis. AIDS. 2010;24(6):928–30.View ArticlePubMedGoogle Scholar
  22. Diez M. Late diagnosis of HIV infection. Revista Espanola de Sanidad Penitenciaria. 2011;2:35–7.Google Scholar
  23. Girardi E, Sabin CA, Monforte AA. Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing. J Acquir Immune Defic Syndr. 2007;46(Suppl 1):S3–8.View ArticlePubMedGoogle Scholar
  24. MOH, UNAIDS, WHO. Update on the HIV/AIDS epidemic and response in China. 2011. Chinese.Google Scholar
  25. Tucker JD, Yang L-G, Yang B, et al. Prior HIV testing among STD patients in Guangdong Province, China: opportunities for expanding detection of sexually transmitted HIV infection. Sex Transm Dis. 2012;(3):182–7.Google Scholar
  26. Ma Y, Zhang F, Zhao Y, et al. Cohort profile: the Chinese national free antiretroviral treatment cohort. Int J Epidemiol. 2010;4:973–9.View ArticleGoogle Scholar
  27. Zhang Y, Dou Z, Sun K, et al. Association between missed early visits and mortality among patients of China National Free Antiretroviral Treatment Cohort. J Acquir Immune Defic Syndr. 2012;(1):59–67.Google Scholar
  28. Jiang Y, Qiu M, Zhang G, et al. Quality assurance in the HIV/AIDS laboratory network of China. Int J Epidemiol. 2010;39(Suppl 2):ii72–8.PubMedPubMed CentralGoogle Scholar
  29. Zhang F, Dou Z, Ma Y, et al. Five-year outcomes of the China national free antiretroviral treatment program. Ann Intern Med. 2009;(4):241–51.Google Scholar
  30. Grigoryan A, Hall HI, Durant T, et al. Late HIV diagnosis and determinants of progression to AIDS or death after HIV diagnosis among injection drug users, 33 US states, 1996-2004. PLoS One. 2009;2:e4445.View ArticleGoogle Scholar
  31. Wohl AR, Tejero J, Frye DM. Factors associated with late HIV testing for Latinos diagnosed with AIDS in Los Angeles. AIDS Care. 2009;(9):1203–10.Google Scholar
  32. Chadborn TR, Delpech VC, Sabin CA, et al. The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000-2004). AIDS. 2006;(18):2371–9.Google Scholar
  33. Centers for Disease Control and Prevention (CDC). Evolution of HIV/AIDS prevention programs--United States, 1981-2006. MMWR Morb Mortal Wkly Rep. 2006;21:597–603.Google Scholar
  34. Bunnell R, Mermin J, De Cock KM. HIV prevention for a threatened continent: implementing positive prevention in Africa. JAMA. 2006;(7):855–8.Google Scholar
  35. Levi J. Ensuring timely access to care for people with HIV infection: a public health imperative. Am J Public Health. 2002;(3):339–40.Google Scholar
  36. Scognamiglio P, Chiaradia G, Carli GD, et al. The potential impact of routine testing of individuals with HIV indicator diseases in order to prevent late HIV diagnosis. BMC Infect Dis. 2013;13:473.View ArticlePubMedPubMed CentralGoogle Scholar
  37. Camoni L, Raimondo M, Regine V, et al. Late presenters among persons with a new HIV diagnosis in Italy, 2010–2011. BMC Public Health. 2013;(1):1–6.Google Scholar
  38. Supervie V. Improving prevention and early diagnosis. BMC Infect Dis. 2014;14(Suppl 2):S6.View ArticlePubMed CentralGoogle Scholar
  39. Ma Y, Dou Z, Guo W, et al. The Human Immunodeficiency Virus Care Continuum in China:1985–2015. Clin Infect Dis. 2018;6:833–9.View ArticleGoogle Scholar
  40. Harris J, Khatri R. Late diagnosis of HIV in the United Kingdom: an evidence review. 2015. https://core.ac.uk/download/pdf/34724457.pdf. Accessed 12 Oct 2017.
  41. Saracino A, Tartaglia A, Trillo G, et al. Late presentation and loss to follow-up of immigrants newly diagnosed with HIV in the HAART era. J Immigr Minor Health. 2014;(4):751–5.Google Scholar
  42. Liu Y, Wu Z, Mao Y, et al. Quantitatively monitoring AIDS policy implementation in China. Int J Epidemiol. 2010;39(Suppl 2):ii90–6.PubMedPubMed CentralGoogle Scholar
  43. Mugavero MJ, Castellano C, Edelman D, et al. Late diagnosis of HIV infection: the role of age and sex. Am J Med. 2007;(4):370–3.Google Scholar
  44. Delpierre C, Cuzin L, Lauwers-Cances V, et al. High-risk groups for late diagnosis of HIV infection: a need for rethinking testing policy in the general population. AIDS Patient Care STDs. 2006;(12):838–47.Google Scholar
  45. Schwarcz S, Hsu L, Dilley JW, et al. Late diagnosis of HIV infection: trends, prevalence, and characteristics of persons whose HIV diagnosis occurred within 12 months of developing AIDS. J Acquir Immune Defic Syndr. 2006;(4):491–4.Google Scholar
  46. Zhang XF, Liu XZ, Tao XR, et al. The epidemiological study on human immunodeficiency virus infection among paid blood donors living in Shandong provincial China comprehensive response project areas. Zhonghua Liu Xing Bing Xue Za Zhi 2005;5:314–316. Chinese.Google Scholar
  47. Zhao F, Wang Z, Li WJ. Human immunodeficiency virus type 1 subtypes prevalence in Central China. Yonsei Med J. 2009;(5):644–9.Google Scholar
  48. State Council of the People’s Republic of China. Further strengthening on AIDS prevention and treatment. 2010. http://www.gov.cn/zwgk/2011-02/16/content_1804536.htm. Chinese.
  49. Ministry of Health of the People’s Republic of China. Carry out the program for the prevention and control of HIV/AIDS among men who have sex with men. 2008. http://www.gov.cn/zwgk/2008-03/28/content_931266.htm. Chinese.
  50. Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord, Young J, Psichogiou M, et al. CD4 cell count and the risk of AIDS or death in HIV-infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. PLoS Med. 2012;3:e1001194.Google Scholar
  51. Guiguet M, Boue F, Cadranel J, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol. 2009;(12):1152–9.Google Scholar
  52. Li M, Tang W, Bu K, et al. Mortality among people living with HIV and AIDS in China: implications for enhancing linkage. Sci Rep. 2016;6:28005.View ArticlePubMedPubMed CentralGoogle Scholar
  53. Long EF, Brandeau ML, Owens DK. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med. 2010;(12):778–89.Google Scholar
  54. Wu Z, Wang Y, Mao Y, et al. The integration of multiple HIV/AIDS projects into a coordinated national programme in China. Bull World Health Organ. 2011;(3):227–33.Google Scholar
  55. Thanawuth N, Chongsuvivatwong V. Late HIV diagnosis and delay in CD4 count measurement among HIV-infected patients in southern Thailand. AIDS Care. 2008;(1):43–50.Google Scholar
  56. Tang H, Mao Y, Shi CX, et al. Baseline CD4 cell counts of newly diagnosed HIV cases in China: 2006-2012. PLoS One. 2014;6:e96098.View ArticleGoogle Scholar
  57. Wu Z. New challenge and complex situation on HIV/AIDS control and prevention in China. Chin J Public Health. 2011;12:1505–7. ChineseGoogle Scholar
  58. Rothman KJ, Greenland S, Lash TL. Chapter 9. Validity in epidemiologic methods. Lippincott Williams & Wilkins. 2008:p352–8.Google Scholar

Copyright

© The Author(s). 2018

Advertisement